Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis has announced that after consultation with the healthcare authorities, the Phase III program for the GLP-1 agonist AVE0010/ZP10 licensed from Zealand Pharma will begin in the first quarter of 2008.
Subscribe to our email newsletter
The program will include over 3,000 diabetic patients and will evaluate a once-a-day injection of AVE0010/ZP10 in combination with the principal existing treatments (metformin, sulfonylurea, insulin), as well as a comparison with exenatide and a monotherapy study.
Filing for approval is expected in 2010. A prolonged release formulation is currently being evaluated in Phase I. AVE0010/ZP10 is a glucagon-like peptide 1, or ‘GLP-1’, receptor agonist developed for subcutaneous injection treatment of Type 2 diabetes and incorporates Zealand Pharma’s ‘SIP’ technology.